Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance

European Journal of Internal Medicine

Volumn 20, Issue 5, 2009, Pages 478-481

  Elefsiniotis, I ^a,b   Buti, M ^b   Jardi, R ^b   Vezali, E ^a   Esteban, R ^b  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adefovir; HBV; HCC; Lamivudine; Resistance; Surveillance

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; LAMIVUDINE;

ADULT; ARTICLE; ASCITES; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG MECHANISM; ECHOGRAPHY; FEMALE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HIGH RISK PATIENT; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68949172074     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.12.013     Document Type: Article

References (28)

1. Lok A.S.F. Chronic hepatitis B. N Engl J Med 346 (2002) 1682-1683
2. Iloeje U., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
3. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
4. Conjeevaram H.S., and Lok A.S.F. Management of chronic hepatitis B. J Hepatol 38 (2003) S90-S103
5. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A 1 year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
6. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
7. Shaw T., Bowden S., and Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?. Gastroenterology 126 (2004) 343-350
8. Lai C.L., Dienstag J.L., Schiff E.R., Leung N.W., Atkins M., Hunt C., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
9. Lok A.S., Lai C.L., Leung N.W., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
10. Leung N.W.Y., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
11. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
12. Liaw Y.F., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
13. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
14. Hadziyannis S., Tassopoulos N., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
15. Peters M.G., Hann H.W., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
16. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
17. Locarnini S., Qi X., Arterbum S., Snow A., Brosgart A., Currie C.L., et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (abstract). J Hepatol 42 Suppl 2 (2005) A17
18. Westland C.E., Yang H., Delaney W.E., Gibbs C.S., Miller M.D., Wulfsohn M., et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38 (2003) 96-103
19. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
20. Fung S.K., Andreone P., Han S., Rajender Reddy K., Regev A., Keeffe E.B., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
21. Fung S.K., Chae H.B., Fontana R., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
22. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotyping resistance to lamivudine. Hepatology 42 (2005) 1414-1419
23. Papatheodoridis G., Dimou E., Dimakopoulos K., Manolakopoulos S., Rapti I., Kitis G., et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analogue therapy starting with lamivudine. Hepatology 42 (2005) 121-129
24. Chu C.M., and Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 2 (2006) 142-152
25. Pungpapong S., Kim R.W., and Poterucha J.J. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 82 8 (2007) 967-975
26. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
27. Buti M., Elefsiniotis I., Jardi R., Vargas V., Rodriguez-Frias F., Schapper M., et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine resistant chronic hepatitis B patients. J Hepatol 47 3 (2007) 366-372
28. Yeon J.E., Yoo W., Hong S.P., Chang Y.J., Yu S.K., Kim J.H., et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55 (2006) 1488-1495